Twinvir Tablet 90 mg+400 mg is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adult patients. It is used as an oral antiviral therapy to help eliminate hepatitis C virus and improve liver health.
Hepatic viral infections (Hepatitis C)
Twinvir Tablet is a fixed-dose combination of two direct-acting antiviral agents. One component is an HCV NS5A inhibitor, while the other is sofosbuvir, a nucleotide analog inhibitor of the HCV NS5B RNA-dependent polymerase. This dual mechanism interferes with viral replication at different stages of the hepatitis C virus life cycle.
After oral administration, peak plasma concentrations of the NS5A inhibitor are typically achieved within approximately 4 to 4.5 hours.
রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন
One tablet containing 90 mg of Twinvir and 400 mg of sofosbuvir taken orally once daily
Can be taken with or without food
Dose recommendations cannot be made for patients with severe renal impairment or end-stage renal disease.
Twinvir Tablet is contraindicated in patients with known hypersensitivity to Twinvir, sofosbuvir, or any other component of the formulation.
Coadministration with amiodarone is not recommended due to the risk of serious symptomatic bradycardia. Use with other medicinal products containing sofosbuvir is also not recommended.
The most commonly reported adverse reactions, occurring in 10% or more of patients, include:
Fatigue
Headache
Nausea
Diarrhea
Insomnia
These effects were observed during treatment durations of 8, 12, or 24 weeks.
Twinvir Tablet is classified as Pregnancy Category B. There are no adequate and well-controlled studies in pregnant women. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
It is not known whether Twinvir or its metabolites are excreted in human breast milk, so caution should be exercised when administered to nursing mothers.
রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন
Serious symptomatic bradycardia has been reported when this combination is used with amiodarone, especially in patients with underlying cardiac disease, those receiving beta-blockers, or those with advanced liver disease. If no alternative treatment options are available, close cardiac monitoring is recommended.
Pediatric patients: Safety and effectiveness have not been established
Geriatric patients: No overall differences in safety or effectiveness compared to younger adults; no dosage adjustment is required
Store in a cool and dry place. Protect from light and moisture. Keep out of the reach of children.
Login Or Registerto submit your questions to seller
No none asked to seller yet